We tested this hypothesis by exploring the GEP differences among high‐ and low‐expressing WT1 samples in two large AML series and next attempted to predict AML outcome using a gene signature and a gene expression score determined from high WT1 expression. The gene discussed is WT1; the disease is acute myeloid leukemia.